For the quarter ending 2025-09-30, UTMD had $2,088K increase in cash & cash equivalents over the period. $3,851K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income | 2,631 | 6,089 |
| Depreciation | 209 | 405 |
| Amortization | 545 | 1,048 |
| Provision for (recovery of) losses on accounts receivable | 402 | -7 |
| Amortization of right of use assets | 15 | 26 |
| Deferred income taxes | -281 | -360 |
| Stock-based compensation expense | 94 | 168 |
| Tax benefit attributable to exercise of stock options | 0 | 0 |
| Accounts receivable and other receivables | 506 | -409 |
| Inventories | -101 | -908 |
| Prepaid expenses and other current assets | 93 | -145 |
| Accounts payable | 32 | 37 |
| Accrued expenses | 729 | -1,531 |
| Total adjustments | 1,247 | 1,248 |
| Net cash provided by operating activities | 3,878 | 7,337 |
| Property and equipment | 27 | 235 |
| Intangible assets | 0 | 0 |
| Property and equipment | 0 | 0 |
| Net cash used in investing activities | -27 | -235 |
| Proceeds from issuance of common stock - options | 0 | 0 |
| Common stock purchased and retired | 653 | 6,708 |
| Payment of dividends | 988 | 2,018 |
| Net cash used in financing activities | -1,641 | -8,726 |
| Effect of exchange rate changes on cash | -122 | 827 |
| Net increase/(decrease) in cash and cash equivalents | 2,088 | -797 |
| Cash and cash equivalents at beginning of period | 82,976 | - |
| Cash and cash equivalents at end of period | 84,267 | - |
UTAH MEDICAL PRODUCTS INC (UTMD)
UTAH MEDICAL PRODUCTS INC (UTMD)